These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8198875)

  • 21. Antibodies and resistance to natural HIV infection.
    Nabel GJ; Sullivan NJ
    N Engl J Med; 2000 Oct; 343(17):1263-5. PubMed ID: 11071680
    [No Abstract]   [Full Text] [Related]  

  • 22. The next steps in HIV vaccine development.
    Ada G; Koff W; Petricciani J
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1317-9. PubMed ID: 1466949
    [No Abstract]   [Full Text] [Related]  

  • 23. Novel campaign to test live HIV vaccine.
    Cohen J
    Science; 1997 Aug; 277(5329):1035. PubMed ID: 9289848
    [No Abstract]   [Full Text] [Related]  

  • 24. Attenuated retrovirus vaccines and AIDS.
    Van Rompay KK; Spinner A; Otsyula M; McChesney MB; Marthas ML
    Science; 1995 Nov; 270(5239):1218-9; author reply 1220-2. PubMed ID: 7502051
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative approach to retroviral vaccines.
    Burny A
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):389-92. PubMed ID: 8882316
    [No Abstract]   [Full Text] [Related]  

  • 26. Concerning the anti-major histocompatibility complex approach to HIV type 1 vaccine design.
    Luscher MA; Dela Cruz CS; MacDonald KS; Barber BH
    AIDS Res Hum Retroviruses; 1998 May; 14(7):541-4. PubMed ID: 9591707
    [No Abstract]   [Full Text] [Related]  

  • 27. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
    Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
    J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conditional live virus as a novel approach towards a safe live attenuated HIV vaccine.
    Das AT; Zhou X; Vink M; Klaver B; Berkhout B
    Expert Rev Vaccines; 2002 Oct; 1(3):293-301. PubMed ID: 12901570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucosal immunity, HIV transmission, and AIDS.
    Miller CJ; McGhee JR; Gardner MB
    Lab Invest; 1993 Feb; 68(2):129-45. PubMed ID: 8441249
    [No Abstract]   [Full Text] [Related]  

  • 30. Fifty volunteer for live-vaccine trial.
    James JS
    AIDS Treat News; 1997 Oct; (No 280):1-2. PubMed ID: 11364735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paradigm change in immune correlation: cellular or humoral?
    Matsuo K; Yamamoto N
    Expert Rev Vaccines; 2010 Sep; 9(9):985-7. PubMed ID: 20822339
    [No Abstract]   [Full Text] [Related]  

  • 32. Attenuated retrovirus vaccines and AIDS.
    Marx PA
    Science; 1995 Nov; 270(5239):1219-20; author reply 1220-2. PubMed ID: 7502054
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
    Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
    AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Will there be a live-attenuated HIV vaccine available for human safety trials by the year 2000? Interview by Gordon Nary.
    Desrosiers RC
    J Int Assoc Physicians AIDS Care; 1998 Nov; 4(11):22-3. PubMed ID: 11366120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccines against human immunodeficiency virus--progress and prospects.
    Letvin NL
    N Engl J Med; 1993 Nov; 329(19):1400-5. PubMed ID: 8413438
    [No Abstract]   [Full Text] [Related]  

  • 36. First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in nonhuman primates: progress in first and second order studies.
    Warren JT; Dolatshahi M
    J Med Primatol; 1993; 22(2-3):203-35. PubMed ID: 8411110
    [No Abstract]   [Full Text] [Related]  

  • 37. [Live attenuated viruses: a new strategy for vaccination against AIDS].
    Molina JM
    Pathol Biol (Paris); 1993 Jun; 41(6):513-4. PubMed ID: 8247628
    [No Abstract]   [Full Text] [Related]  

  • 38. Simian immunodeficiency virus live and inactivated experimental vaccines.
    Norley S; Beer B; Binninger-Schinzel D; Vogel T; Siegel F; Cosma C; König H; Megede JZ; Kurth R
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):447-9. PubMed ID: 8882331
    [No Abstract]   [Full Text] [Related]  

  • 39. Preventive HIV-1 vaccines: where are we going?
    Kent SJ
    Int J STD AIDS; 1998 Dec; 9(12):715-9. PubMed ID: 9874116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus.
    Dale CJ; De Rose R; Stratov I; Chea S; Montefiori DC; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Law M; Kent SJ
    J Virol; 2004 Dec; 78(24):13819-28. PubMed ID: 15564490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.